Post-Marketing Analysis of Peripheral Neuropathy Burden with New-Generation Proteasome Inhibitors Using the FDA Adverse Event Reporting System

Proteasome inhibitors (PIs) are an integral component of multiple myeloma therapies. Peripheral neuropathy (PN) is a well-known consequence of PIs, most frequently reported with earlier generations such as bortezomib (BTZ). There is a paucity of data highlighting the risk of developing PN with the n...

Descripción completa

Detalles Bibliográficos
Autores principales: Mina, Syeda A., Muhsen, Ibrahim N., Burns, Ethan A., Sarfraz, Humaira, Pingali, Sai Ravi, Xu, Jiaqiong, Hashmi, Shahrukh K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Galenos Publishing 2021
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8386311/
https://www.ncbi.nlm.nih.gov/pubmed/34190655
http://dx.doi.org/10.4274/tjh.galenos.2021.2021.0052

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8386311/
https://www.ncbi.nlm.nih.gov/pubmed/34190655
http://dx.doi.org/10.4274/tjh.galenos.2021.2021.0052

Ejemplares similares